Zai Lab

ZLAB · HONG

$24.03+$1.99 (+9.03%)TodayMarket closed · Oct 23, 7:39 PM ET

Prev close $22.04

About ZLAB

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The firm is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The firm has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The firm conducts its businesses within domestic and overseas markets.

Employees: 1,194
Headquarters: Shanghai, Shanghai
Listed: Sep 28, 2020
Sector: Health Care
Industry: Biotechnology
Website: zailaboratory.com

Leadership

Zai Lab executives
Name	Title	Since	Age
Du Ying	—	—	59
Joshua Smiley	—	—	54
Yajing Chen	—	—	56
Rafael Amado	—	—	60
F. Ty Edmondson	—	—	58
Au-yeung Nelly	—	—	—
John Diekman	—	—	81
Richard Gaynor	—	—	74
William Lis	—	—	59
Scott Morrison	—	—	66
Leon Moulder	—	—	66
Michel Vounatsos	—	—	62
Leung Wing-Yu	—	—	53
Peter Wirth	—	—	73
Christine Chiou	—	2023	—

Revenue by product and region

Fiscal year ended Dec 31, 2021: $144.10M total revenue

By product

Zejula [Member]$93.58M64.9%
Optune [Member]$38.90M27.0%
Qinlock [Member]$11.62M8.1%
Nuzyra [Member]$3.00K0.0%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.